ArticleDiabetologia2017
Bladder cancer in the EMPA-REG OUTCOME trial.
Article in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Long-Term Empagliflozin Treatment (50 Days) Attenuates Protease Activity, Migration, and Stemness-Associated Phenotypes in BFTC-909 Renal Pelvis Transitional Cell Carcinoma Cells.Journal of Cancer · 2026Article
- Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi-country European study.Diabetes, obesity & metabolism · 2025Observational
- A review of the safety of sodium-glucose co-transporter-2 inhibitors.Diabetes, obesity & metabolism · 2025Review
- Anti-Diabetic Therapies and Cancer: From Bench to Bedside.Biomolecules · 2024Review
- Applications of SGLT2 inhibitors beyond glycaemic control.Nature reviews. Nephrology · 2024Review
- Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024Review
- Obesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions.Archives of endocrinology and metabolism · 2023Review
- Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study.Diabetes care · 2022Article
- The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.Cardiovascular diabetology · 2022Review
- Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews.Therapeutic advances in drug safety · 2021Review
- Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.Advances in therapy · 2020Article
- Review of Associations Between Type 2 Diabetes and Cancer.Clinical diabetes : a publication of the American Diabetes Association · 2020Article
- The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Review
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.Diabetologia · 2018Review
- Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter].Diabetologia · 2017Article
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.